Oncology Development Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

Oncology Pipeline & Trials

Compound Name	Indication	Phase	Submission Type	Compound Type
PF-05280586, a potential biosimilar to Rituxan� /MabThera� (rituximab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: CD20 Antigen Antagonist Go to clinical trial	Follicular Lymphoma (Biosimilar) (E.U.)	Registration	Biosimilar	Biosimilar
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (E.U.)	Registration	Product Enhancement	Biologic
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist Go to clinical trial	Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Project advanced	Registration	New Molecular Entity	Small Molecule
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Metastatic Hormone Sensitive Prostate Cancer (E.U.) Project advanced	Registration	Product Enhancement	Small Molecule
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Non-Small Cell Lung Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Gastric Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Urothelial Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 3	Product Enhancement	Biologic
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist Go to clinical trial	Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.)	Phase 3	Product Enhancement	Small Molecule
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor Go to clinical trial	High Risk Early Breast Cancer	Phase 3	Product Enhancement	Small Molecule
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor Go to clinical trial	Early Breast Cancer in Adjuvant Setting	Phase 3	Product Enhancement	Small Molecule
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor Go to clinical trial	ER+/HER2+ Breast Cancer	Phase 3	Product Enhancement	Small Molecule
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor Go to clinical trial	1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.)	Phase 3	Product Enhancement	Small Molecule
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor Go to clinical trial	Combo w/ Xtandi (enzalutamide) for: 1st Line Metastatic Castration-Resistant Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Metastatic Hormone Sensitive Prostate Cancer (U.S.)	Phase 3	Product Enhancement	Small Molecule
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Non-metastatic High Risk Hormone Sensitive Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Merkel Cell Carcinoma (MCC) (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	Combo w/ PF-04518600 (OX40) for various solid tumors (Biologic)	Phase 2	Product Enhancement	Biologic